Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
Zhejiang DTRM Biopharma
Oncternal Therapeutics, Inc
Celgene
Vifor Pharma
miRagen Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc
University of Michigan Rogel Cancer Center
miRagen Therapeutics, Inc.
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Barbara Ann Karmanos Cancer Institute
Baylor College of Medicine
City of Hope Medical Center
Seagen Inc.
Ariad Pharmaceuticals
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
HemaQuest Pharmaceuticals Inc.